Cytokine-binding proteins (CBPs) block the ability of cytokines to int
eract with their receptors. These agents can potentially provide a mea
ns of treating pathological conditions that have a significant cytokin
e involvement. However, a major drawback of such approaches relates to
the fact that CBPs stabilize the cytokine in the form of a cytokine-C
BP complex in vivo. Here, Bernard Klein and Herve Brailly discuss the
possibility that CBPs behave either as agonists or antagonists accordi
ng to their pharmacokinetic characteristics in vivo, and suggest a mec
hanism by which stable complexes might be cleared from the system.